PMID- 34920109
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 1530-891X (Print)
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 28
IP  - 2
DP  - 2022 Feb
TI  - SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared 
      With Controls.
PG  - 191-198
LID - S1530-891X(21)01416-6 [pii]
LID - 10.1016/j.eprac.2021.12.009 [doi]
AB  - OBJECTIVE: Data for the association between diabetes and severe acute respiratory 
      syndrome coronavirus 2 (SARS-CoV-2) susceptibility are conflicting. We aimed to 
      evaluate this association using an analytical cross-sectional study design. 
      METHODS: Study participants were recruited from endocrine clinics of our hospital 
      and belonged to 3 groups: group 1 (type 1 diabetes mellitus [T1DM]), group 2 
      (type 2 diabetes mellitus [T2DM]), and group 3 (controls). All participants 
      submitted blood samples for SARS-CoV-2 S1/S2 immunoglobulin G antibody test 
      (LIAISON; DiaSorin) and were interviewed for a history of documented infection. 
      RESULTS: We evaluated a total of 643 participants (T1DM, 149; T2DM, 160; control, 
      334; mean age, 37.9 +/- 11.5 years). A total of 324 (50.4%) participants were 
      seropositive for SARS-CoV-2. The seropositivity rate was significantly higher in 
      the T1DM (55.7% vs 44.9%, P = .028) and T2DM (56.9% vs 44.9%, P = .013) groups 
      than in the control group. The antibody levels in seropositive participants with 
      T1DM and T2DM were not significantly different from those in seropositive 
      controls. On multivariable analysis, low education status (odds ratio [OR], 1.41 
      [95% CI, 1.03-1.94]; P = .035), diabetes (OR, 1.68 [95% CI, 1.20-2.34]; P = 
      .002), and overweight/obesity (OR, 1.52 [95% CI, 1.10-2.10]; P = .012) showed a 
      significant association with SARS-CoV-2 seropositivity. The association between 
      diabetes and SARS-CoV-2 seropositivity was found to further increase in 
      participants with coexisting overweight/obesity (adjusted OR, 2.63 [95% CI, 
      1.54-4.47]; P < .001). CONCLUSION: SARS-CoV-2 seropositivity, assessed before the 
      onset of the national vaccination program, was significantly higher in 
      participants with T1DM and T2DM than in controls. The antibody response did not 
      differ between seropositive participants with and without diabetes. These 
      findings point toward an increased SARS-CoV-2 susceptibility for patients with 
      diabetes, in general, without any differential effect of the diabetes type.
CI  - Copyright (c) 2021 AACE. Published by Elsevier Inc. All rights reserved.
FAU - Goyal, Alpesh
AU  - Goyal A
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Gupta, Yashdeep
AU  - Gupta Y
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Kalaivani, Mani
AU  - Kalaivani M
AD  - Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Praveen, Pradeep A
AU  - Praveen PA
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Ambekar, Samita
AU  - Ambekar S
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Tandon, Nikhil
AU  - Tandon N
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical 
      Sciences, New Delhi, India. Electronic address: nikhil_tandon@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20211214
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - SARS-CoV-2
MH  - Seroepidemiologic Studies
PMC - PMC8669945
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - diabetes
OT  - obesity
OT  - type 1 diabetes
OT  - type 2 diabetes
EDAT- 2021/12/18 06:00
MHDA- 2022/02/01 06:00
PMCR- 2021/12/14
CRDT- 2021/12/17 20:14
PHST- 2021/08/28 00:00 [received]
PHST- 2021/11/27 00:00 [revised]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2021/12/18 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/12/17 20:14 [entrez]
PHST- 2021/12/14 00:00 [pmc-release]
AID - S1530-891X(21)01416-6 [pii]
AID - 10.1016/j.eprac.2021.12.009 [doi]
PST - ppublish
SO  - Endocr Pract. 2022 Feb;28(2):191-198. doi: 10.1016/j.eprac.2021.12.009. Epub 2021 
      Dec 14.